Teladoc Health (TDOC) EBIT (2014 - 2026)

Teladoc Health has disclosed EBIT across 13 years of filings, most recently posting -$37.1 million for Q2 2026.

• In Q2 2026, EBIT rose 31.8% year-over-year to -$37.1 million; the TTM figure through Jun 2026 stood at -$186.8 million (up 30.19% YoY), while the FY2025 annual figure was -$263.0 million, up 74.24% from the prior year.
• EBIT came in at -$37.1 million for Q2 2026 at Teladoc Health, up from -$61.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$35.1 million in Q4 2023 to a low of -$6.7 billion in Q1 2022.
• Average EBIT over 5 years is -$849.1 million, with a median of -$68.2 million recorded in 2023.
• Year-over-year, EBIT sank 9109.86% in 2022 and surged 99.08% in 2023.
• Over 5 years, EBIT stood at -$3.8 billion in 2022, then surged by 99.08% to -$35.1 million in 2023, then plunged by 37.44% to -$48.2 million in 2024, then rose by 25.34% to -$36.0 million in 2025, then fell by 3.04% to -$37.1 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$37.1 million in Q2 2026, -$61.8 million in Q1 2026, and -$36.0 million in Q4 2025.